Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Graphite Bio Inc | GRPH | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.18 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.18 | 3.18 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 2.0101 - 4.26 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 3.18 | USD |
Graphite Bio Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 918.98M | 58.24M | - | 0 | -124.65M | -2.14 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Graphite Bio News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GRPH Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 2.79 | 4.26 | 2.57 | 3.47 | 394,921 | 0.39 | 13.98% |
| 6 Months | 2.49 | 4.26 | 2.0101 | 2.97 | 249,104 | 0.69 | 27.71% |
| 1 Year | 3.13 | 4.26 | 2.0101 | 2.83 | 181,286 | 0.05 | 1.60% |
| 3 Years | 22.10 | 34.00 | 1.59 | 7.01 | 285,970 | -18.92 | -85.61% |
| 5 Years | 22.10 | 34.00 | 1.59 | 7.01 | 285,970 | -18.92 | -85.61% |
Graphite Bio Description
| Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its lead product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. All of the company's long-lived assets are based in the United States. |
